---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-035141"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2023-12-21T23:59:59+00:00"
generated_at: "2026-06-07T09:08:12.568362+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Moleculin Biotech prices $4.5M registered direct offering and concurrent private placement

## Summary
- Gross proceeds ~$4.5M from sale of 7,044,836 shares/pre-funded warrants at effective price of $0.64 (institutional) and $0.69 (insiders).
- Concurrent private placement of warrants to purchase up to 14,089,672 common shares at $0.64, exercisable from stockholder approval, 5-year term.
- Expected closing December 26, 2023; Maxim Group LLC serves as placement agent with 7% fee.
- CEO, CFO, directors, and employees purchased 326,086 shares at $0.69 per unit, participating alongside institutional investor.
- Company also amended bylaws to change voting standard to majority of votes cast for most stockholder matters.

## SEC filing metadata
- accession: 0001437749-23-035141
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2023-12-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774923035141/0001437749-23-035141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774923035141/mbrx20231220_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-035141
- JSON: https://secwatch.observer/filing/0001437749-23-035141.json
- Plain text: https://secwatch.observer/filing/0001437749-23-035141.txt

## Key facts
- Governance Changes
  Moleculin Biotech, Inc.: The Board adopted the Fourth Amended and Restated Bylaws, including a clarification that matters presented to stockholders (other than director elections) shall be decided by the affirmative vote of a majority of votes cast (excluding abstentions and broker nonvotes) (effective 2023-12-20).
  - Change: bylaw amendment
  - Effective: 2023-12-20
  source text: On December 20, 2023, the Board of Directors of the Company adopted the Fourth Amended and Restated Bylaws of Moleculin Biotech, Inc. (as amended and restated, the “Bylaws”), effective on such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1659617/000143774923035141/0001437749-23-035141-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.